Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CoDa Therapeutics' NEXAGON was well tolerated and demonstrated an increase in complete healing in the patients with chronic venous leg ulcers in the Phase 2b study.
Subscribe to our email newsletter
The results of vehicle-controlled, double-blind, randomised Phase 2b study support the advancement of Nexagon into Phase 3 registration trials.
The UNC Limb Salvage/Wound Healing Center medical director and University of North Carolina division of vascular surgery professor and chief Dr. William Marston said CoDa’s Phase 2b clinical results reflect a well-designed and executed dosing phase study.
"This data will provide clear information to choose an optimal dose and patient profile to move to a pivotal clinical trial," Marston added.
Company is designing plans for Phase 3 study of once-a-week topical drug candidate that is designed to increase the incidence of wound healing and rapid healing compared to existing therapeutic techniques.
CoDa Chief Medical Officer Dr. David Eisenbud and the American Academy of Wound Management former president said, "The positive results from the NOVEL2 study substantiate our prior findings from previous VLU studies and suggest that NEXAGON could become a game changer: the first prescription medication to enhance the healing of venous leg ulcers."